This therapeutic approach targets nucleocytoplasmic transport (NCT) dysfunction, a fundamental mechanism underlying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The nuclear pore complex (NPC) and associated transport proteins are compromised in these disorders, leading to nuclear-cytoplasmic mislocalization of RNAs and proteins, including TDP-43 and FUS.
This therapeutic approach targets nucleocytoplasmic transport (NCT) dysfunction, a fundamental mechanism underlying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The nuclear pore complex (NPC) and associated transport proteins are compromised in these disorders, leading to nuclear-cytoplasmic mislocalization of RNAs and proteins, including TDP-43 and FUS.
Rationale
Core pathology identified: Nuclear pore dysfunction is documented in ALS/FTD brain tissue[@dort2018][@woermann2016]
Multiple genetic hits: ALS/FTD mutations in FUS, TDP-43 (TARDBP), and C9orf72 all impair NCT[@freibaum2015]
Nuclear pore compromise: NPC components (NUP358, NUP62, NUP205) show altered expression/localization in disease[@gasset2019][@meech2019]
RNP granule trafficking: Defective NCT contributes to stress granule pathology and cytoplasmic protein aggregation
10-Dimension Rubric Scoring
| Dimension | Score | Rationale | |-----------|----:|-----------| | Novelty | 9 | Emerging mechanism; limited therapeutic development | | Mechanistic Rationale | 9 | Strong genetic and neuropathology evidence | | Root-Cause Coverage | 8 | Addresses upstream nuclear integrity | | Delivery Feasibility | 6 | Large molecules need CNS delivery; small molecules promising | | Safety Plausibility | 7 | Nuclear transport modulators being developed in oncology | | Combinability | 9 | Synergistic with TDP-43, FUS, C9orf72 targeted approaches | | Biomarker Availability | 7 | Nuclear/cytoplasmic ratio of TDP-43 in CSF or neurons | | De-risking Path | 6 | Early stage; needs validation | | Multi-disease Potential | 8 | AD, PD, Huntington disease all show NCT defects[@lin2013] | | Patient Impact | 9 | High unmet need in ALS/FTD |
Total Score: 78/100
Disease Coverage
| Disease | Coverage | Rationale | |---------|----------:|-----------| | ALS | 10 | Core mechanism in sporadic and familial ALS | | FTD | 10 | TDP-43 and FUS pathology linked to NCT dysfunction | | AD | 6 | NPC dysfunction documented in AD models | | PD | 5 | Some evidence of NCT impairment | | Aging | 7 | Age-related nuclear pore alterations |
Mechanism of Action
Nuclear Pore Complex Dysfunction in ALS/FTD
The nuclear pore complex (NPC) regulates all molecular traffic between nucleus and cytoplasm. In ALS/FTD:
[Dort L, Brown N Jr, Nucleocytoplasmic transport dysfunction in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29650441/)
[Gasset N et al, Nuclear pore complexes in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31816951/)
[Woermann J et al, Nuclear pore dysfunction in neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27215269/)
[Freibaum BD et al, FUS and TDP-43 nuclear integrity (2015)](https://pubmed.ncbi.nlm.nih.gov/26542278/)
[Fare M, Rothstein JD, Nucleocytoplasmic trafficking disruption in ALS and FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/39214475/)
[Khalil B et al, Nuclear import receptors as gatekeepers of pathological phase transitions in ALS/FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38956691/)
[Sirtori L et al, Nuclear envelope dysfunction in ALS: mechanisms and therapeutic implications (2024)](https://pubmed.ncbi.nlm.nih.gov/38475892/)